How pharma economics hold back antibiotic development
07 March 2022
Dick Jenkins and other ‘angel’ investors have committed more than £20mn to the development of an experimental drug to tackle life-threatening infections. But they have come up against a substantial hurdle: a need for even more money.
Further reading: Financial Times
Author(s): Andrew Jack
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!
